ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2627

Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease

Akihiko Nakabayashi1, Toru Hirano2, Yoshihiro Hishitani2, Keisuke Hagihara3, Kei Nakai4, Kouji Nishida4 and Atsushi Kumanogoh2, 1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 2Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 3Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 4Department of Ophthalmology, Osaka University Graduate School of Medicine, suita, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, infliximab and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet’s disease. However, prognostic factors remain to be determined.

Methods: Observational study in one institute was conducted in the cohort of patients with Behçet’s disease treated with infliximab. Outcome was defined as failure to recover above 20/50 of visual acuity (VA) at 2 year after the first administration of infliximab. Associations between outcome and baseline characteristics were assessed by bivariable analysis and logistic regression analysis to adjust confounding factors. Significance of each factor was assessed by likelihood ratio test.

Results: Infliximab was initiated in 28 patients between February 2007 and May 2012. Nineteen patients continued to receive infliximab beyond 2 year and could be assessed. Among 38 eyes of 19 patients, 18 eyes could not achieve 20/50 of VA (Figure). Bivariable analysis between the outcome and baseline characteristics demonstrated p-value (p) = 0.53 for sex, p = 0.19 for disease duration, p = 0.43 for HLA-B51, p = 0.97 for C-reactive protein (CRP), p < 0.0001 for VA at the first administration, p = 0.088 for deviation of VA during 6 months before the first administration, p = 0.48 for concomitant use of corticosteroids and p= 0.042 for concomitant use of immunosuppressants such as cyclosporine or methotrexate. Adjusted analysis with confounding factors such as sex, age, disease duration, VA at the first administration and concomitant use of immunosuppressants by logistic regression analysis revealed disease duration (p=0.024) and visual acuity (p < 0.0001) as significant factors (Table). Receiver operating characteristic (ROC) analysis demonstrated 16.5 months of disease duration and 20/140 of visual acuity (Area under the curve: 0.95) for candidate cutoff values.

Conclusion: Disease duration and VA at the first administration of infliximab were the most contributable factors for the prognosis of visual function after 2 years. Cutoff values, 16.5 months of disease duration and 20/140 of VA suggest the importance of ‘windows of opportunity’ in treatment for uveitis of Behçet’s disease.

Figure. Change of visual acuity

Visual acuity

Table. Contributable factors for visual acuity at 2 year

Factor                             p-value

Sex                                    0.41

Age                                    0.42

Disease duration                0.024

Visual acuity                       <0.0001

Immunosuppressants        0.64

*regression logistic analysis and likelihood ratio test


Disclosure:

A. Nakabayashi,
None;

T. Hirano,
None;

Y. Hishitani,
None;

K. Hagihara,
None;

K. Nakai,
None;

K. Nishida,
None;

A. Kumanogoh,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-factors-of-visual-function-in-the-treatment-with-infliximab-for-uveitis-of-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology